CatalYm GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.catalym.com
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
Phase 2
Active, not recruiting
- Conditions
- Bladder CancerAdult Solid Tumor
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT06059547
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University, Milano, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
🇮🇹Istituto Nazionale Tumori IRCCS - Fondazione Pascale, Napoli, Italy
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- Biological: visugromab (CTL-002)
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 274
- Registration Number
- NCT04725474
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt, Medizinische Klinik I, Frankfurt am Main, Germany
🇪🇸Next Oncology, Phase I Unit. IOB - Hospital Quironsalud, Barcelona, Spain
🇨ðŸ‡University Hospital Zurich, Department of Dermatology, Zurich, Switzerland
© Copyright 2025. All Rights Reserved by MedPath